Immunovant, Inc. (IMVT)
NEUTRALFondamental
31
Prix
$43.31
Capitalisation boursière
$9.01B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
0
Exercice clos le 31/03/2026
Résultat net
$-506M
Exercice clos le 31/03/2026
Flux de trésorerie libre
$-407M
Capitaux propres totaux
$853M
Passif total
$104M
Ratio de liquidité général
7.27
Couverture des intérêts
-
Dette/EBITDA
-
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$48.88
Prix actuel
$43.31
Marge de sécurité
+11.4%
Fourchette de juste valeur
$46.43 - $51.32
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
-
ROE
-59.3%
Ratio P/B
12.17
P/FCF
-
Marge brute
-
ROIC
-
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
-
WACC
9.1%
ROIC − WACC
-
Critères d'analyse fondamentale
Réussi (5)
- Price CAGR 15.82%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 82% Buy
Échoué (9)
- EPS shows upward trend
- P/B Ratio 12.17
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -69.6%
- Earnings Surprise avg -5.5%
- Share Dilution 20.4%
- Piotroski F-Score 2/9
Indisponible (13)
- ROIC NaN%
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Operating Margin NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Net Margin Trend (invalid data)
Score F de Piotroski
Préoccupations financières sérieuses
Qualité des bénéfices
Qualité faible : examiner la comptabilité
Dilution du capital
Émission de nouvelles actions, diluant la participation
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board | 46 |
| Dr. Eric Venker M.D., Pharm.D. | CEO & Director | 38 |
| Mr. Tiago M. Girao CPA | Chief Financial Officer | 46 |
| Ms. Melanie Gloria B.S.N. | Chief Operating Officer | 47 |
| Dr. Jay S. Stout M.S., Ph.D. | Chief Technology Officer | 62 |
| Mr. Christopher A. Van Tuyl Esq., J.D. | Chief Legal Officer & Corporate Secretary | 50 |
| Ms. Christine Blodgett | Senior Vice President of Human Resources | - |
| Ms. Becky Merlina | Senior VP & Global Head of Quality | - |
| Ms. Yan Zheng M.S., Ph.D. | Senior Vice President of Biostatistics, Programming & Data Management | - |
| Ms. Sheetal Patel M.B.A., M.D., M.S. | Senior Vice President of Clinical Development | - |
Risque d'audit
4
Risque du conseil
10
Risque de rémunération
9
Risque droits des actionnaires
10
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for IMVT, sourced from Markets Gazette.
- 3/15/2026POSITIVEA Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?
A healthcare hedge fund has significantly increased its stake in Immunovant Inc., acquiring an additional $24.5 million worth of stock. Immunovant is a clinical-stage biopharmaceutical company focused on developing antibody therapies for autoimmune diseases. Its lead candidate is currently undergoing Phase II trials. This substantial investment by a specialized healthcare fund suggests strong conviction in the company's pipeline and future prospects. For investors, this move could signal positive upcoming developments or a favorable risk-reward profile for Immunovant's stock.
- 3/11/2026POSITIVEImmunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish
Immunovant Inc. (IMVT) experienced a significant surge, with its stock price climbing 30%. This upward momentum comes despite a notable insider trimming their stake by $3 million. The company, which focuses on antibody therapies for autoimmune diseases, has seen its lead candidate advance through clinical trials. This progress in its drug development pipeline is a key driver for investor optimism, suggesting potential future revenue streams and market expansion. The stock's performance indicates strong market confidence in Immunovant's therapeutic pipeline and its long-term growth prospects, outweighing the impact of the insider's partial divestment.
via Markets Gazette